fda warning letter compounded semaglutide september 2025 letters glp-1 Fda Warning Letters Glp-1 Compounded September 2025 There's lots going on this month at FDA Have patients been harmed by
Description
In this episode, they go deep on the science of coherent vs

Final thoughts from a mental health perspective Compared to 2023, the conversation around GLP-1s is more grounded and more complex

The combination can significantly reduce appetite and caloric intake, which, if not carefully managed, may lead to dehydration, fatigue, or low blood pressure particularly in individuals also taking antihypertensive medications

doi: 10.1038/nmicrobiol.2016.93 78 RidlonJMKangD-JHylemonPB